HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Revlon

This article was originally published in The Rose Sheet

Executive Summary

Company announces receipt of proposed term loan add-on of $25 mil., bringing the add-on to its existing $700 mil. term loan facility to $100 mil. Revlon reported it was seeking an amendment to its 2004 bank credit agreement during a July 12 preliminary Q2 earnings call (1"The Rose Sheet" July 17, 2006, p. 3). Proposed credit agreement amendment for $25 mil. add-on "is expected to be consummated in late July 2006, subject to market and other customary conditions, including receipt of consents from the appropriate lenders," firm notes. Revlon expects to record a second quarter operating loss of about $55 mil. and a net loss of approximately $95 mil...

Latest Headlines
See All
UsernamePublicRestriction

Register

RS014094

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel